Adverum Biotechnologies, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 23.71 million compared to USD 32.74 million a year ago. Basic loss per share from continuing operations was USD 2.3 compared to USD 3.3 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.19 USD | -2.13% | -18.96% | +22.08% |
Mar. 21 | Adverum Biotechnologies Files $200 Million Mixed Shelf | MT |
Mar. 19 | RBC Cuts Price Target on Adverum Biotechnologies to $2 From $3, Keeps Sector Perform, Speculative Risk | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.08% | 191M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- ADVM Stock
- News Adverum Biotechnologies, Inc.
- Adverum Biotechnologies, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023